- Home
- IKT vs OFS Comparison
IKT vs OFS Comparison
Compare IKT & OFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKT
- OFS
- Stock Information
- Founded
- IKT 2008
- OFS 2001
- Country
- IKT United States
- OFS United States
- Employees
- IKT N/A
- OFS N/A
- Industry
- IKT Biotechnology: Pharmaceutical Preparations
- OFS Finance/Investors Services
- Sector
- IKT Health Care
- OFS Finance
- Exchange
- IKT Nasdaq
- OFS Nasdaq
- Market Cap
- IKT 111.8M
- OFS 95.6M
- IPO Year
- IKT 2020
- OFS 2012
- Fundamental
- Price
- IKT $1.53
- OFS $5.00
- Analyst Decision
- IKT Hold
- OFS
- Analyst Count
- IKT 1
- OFS 0
- Target Price
- IKT N/A
- OFS N/A
- AVG Volume (30 Days)
- IKT 109.4K
- OFS 115.3K
- Earning Date
- IKT 11-14-2025
- OFS 10-30-2025
- Dividend Yield
- IKT N/A
- OFS 13.60%
- EPS Growth
- IKT N/A
- OFS N/A
- EPS
- IKT N/A
- OFS 0.24
- Revenue
- IKT N/A
- OFS $42,970,000.00
- Revenue This Year
- IKT N/A
- OFS N/A
- Revenue Next Year
- IKT N/A
- OFS N/A
- P/E Ratio
- IKT N/A
- OFS $20.74
- Revenue Growth
- IKT N/A
- OFS N/A
- 52 Week Low
- IKT $1.33
- OFS $5.00
- 52 Week High
- IKT $4.20
- OFS $9.80
- Technical
- Relative Strength Index (RSI)
- IKT 47.90
- OFS 22.63
- Support Level
- IKT $1.55
- OFS $5.07
- Resistance Level
- IKT $1.67
- OFS $5.53
- Average True Range (ATR)
- IKT 0.13
- OFS 0.38
- MACD
- IKT 0.01
- OFS -0.05
- Stochastic Oscillator
- IKT 51.16
- OFS 0.00
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
About OFS OFS Capital Corporation
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its business objective is to generate current income and capital appreciation by investing in middle-market companies in the United States. The company focuses on investments in senior secured loans, including first lien, second lien, and unitranche loans, as well as subordinated loans and, to a lesser extent, warrants, and other equity securities.